Rasayan Labs, a San Jose and Nagpur-headquartered startup, announced the launch of its proprietary AI-native platform for computational chemistry and drug discovery at the Institute of Chemical Technology (ICT), Mumbai.
The new platform answers two questions, and answers them real fast: can I make this compound, and should I make it? It unifies that into a single platform spanning AI-powered retrosynthesis, especially powerful for novel structures, with over 13 million reactions, 126 million building blocks, and 110 million patents; ADMET prediction across 1,400+ properties, impurity prediction, and RasayanDraw, a proprietary molecular editor.
